The human papilloma virus causes deadly cancers in both men and women and infects up to 80 percent of the American population. So why is the lifesaving HPV vaccine currently targeted at just the female half of the population?
A milestone recommendation from an influential vaccine advisory panel is set to change that.
Responsible parents will act on this common-sense medical advice, not succumb to antivaccine misinformation and misguided fears that a vaccine guarding against a sexually transmitted virus will promote promiscuity.
Late last month, the Advisory Committee on Immunization Practices recommended that boys and young men -- who can contract the virus and spread it -- get the HPV vaccine, too.
Five years ago, the panel recommended the vaccine for girls and young women. The decision on boys was delayed to gather additional safety and cost-effectiveness data.
The panel is part of the U.S. Centers for Disease Control and Prevention, which has yet to finalize the recommendation but typically does.
This imprimatur will add the HPV vaccine to the roster of routine pediatric shots, though it does not mandate it. It also sets the stage for more health insurers to pay for the three-shot series, which is important, because the cost can be $300 or more.
A generation ago, a shot that prevented cancer -- think about it -- would have been heralded as the remarkable public health advance that it is. Instead, this vaccine's arrival has been greeted with a puzzling shrug by many parents.